The Emerging Role of Immunotherapy in Head and Neck Squamous Cell Cancer

Tejas Suresh, MD, and Barbara Burtness, MD

Abstract

The morbidity and mortality of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) are still high, despite advances in treatment. HNSCC is known to depress the immune system and cause significant impairment in antitumor immunity. Recently, there have been advances in immunotherapy in multiple tumor types, including HNSCC, with the FDA granting approval of 2 checkpoint inhibitors, pembrolizumab (Keytruda) and nivolumab (Opdivo), in the r/m setting. The immunotherapies have durable response rates with a favorable adverse effect profile compared with conventional treatments. Clinical trials are underway to integrate immunotherapy into different steps of management, as well as to partner with other therapies, namely chemotherapy, radiation, surgery, and targeted therapies. This review will focus on the checkpoint inhibitors, combinations of checkpoint inhibitors, and therapeutic vaccines, as well as costimulatory agonists.

AJHO. 2017;13(6):20-27

Introduction

Worldwide, more than 550,000 cases and 380,000 deaths occur annually from head and neck squamous cell carcinoma (HNSCC). In the United States, 63,000 patients are diagnosed annually, and about 13,000 die from the disease. The majority are related to tobacco and alcohol use, but the number of high-risk human papillomavirus (HPV)-associated oropharynx cancers is increasing; these are often identified in clinical trials via staining for the surrogate marker p16. Tumors that are p16-positive (+) have a more favorable prognosis and may require less intense treatment. Patients with HPV-associated cancers are significantly younger, have tumors typically in the tonsillar region or base of tongue, and tend to present with early-stage primary tumors with an increased risk of advanced nodal involvement when compared with HPV-negative (-) patients. HPV-associated tumors are pathologically distinct, with lymphocyte infiltration in the stroma and in tumor nests. Despite advances in treatment, there is still a relatively poor 10-month median overall survival (OS) for recurrent/metastatic (r/m) disease, with some evidence that survival is greater for HPV-associated than HPV-disease. HPV-associated HNSCC can have mutations from expression of apolipoprotein B mRNA editing enzymes or catalytic polypeptide-like cytidine deaminases, which are responsible for DNA editing and cause mutation clusters in multiple tumor types. HPV-HNSCC tends to have mutations caused by smoking. The overall mutation burden is similar in both types of HNSCC, but the specific mutational composition is very different; 5 distinct subtypes have been identified.

HNSCC is associated with multiple alterations in the immune system, potentially resulting in depressed antitumor immunity. These alterations include expression of immune checkpoint molecules, which increase the proportion of immunosuppressive regulatory T cells (Tregs) in the circulation and within the tumor microenvironment, cause dysregulation of T-cell function, alter cytokine production and myeloid dendritic cell (DC) function, and decrease the number of natural killer (NK) cells. Therapies that overcome these immune checkpoints and restore immune function have demonstrated activity in HNSCC, and combination strategies—of more than 1 immunotherapy, or of immunotherapy with conventional therapy—are under active investigation. Immunotherapies currently being studied include checkpoint inhibitors, therapeutic vaccines, costimulatory agonists, adoptive T-cell therapies, and monoclonal antibodies (mAbs). This review will focus on the checkpoint inhibitors, combinations of checkpoint inhibitors, and therapeutic vaccines, as well as costimulatory agonists.

Immune Checkpoints

Tregs are a subset of CD4+CD25+ T cells that express the canonical transcription factor FOXP3. Tregs compose 5% to 10% of CD4+ T cells in the peripheral blood of healthy persons, but in patients with a malignancy, peripheral blood mononuclear cells (PBMCs) may contain up to 25% to 30% of Tregs. Tregs increase has been documented across patients with a variety of malignancies, including HNSCC. Tregs suppress NK cells, DCs, and B-cell function, and are significantly enriched in tumor-infiltrating lymphocytes (TILs) compared with autologous PBMCs in patients with HNSCC, dampening antitumor immunity. Furthermore, they release suppressive cytokines and express cytotoxic T lymphocyte–associated protein 4 (CTLA-4).
Tregs number is increased in HNSCC patients before and after treatment. Interestingly, patients with advanced disease and those who have undergone treatment with curative intent have the same proportions of Tregs in the periphery, suggesting an immune dysregulation by the tumor that does not resolve after treatment. The regulatory PD-1 receptor is expressed on activated T cells. PD-1 signaling is activated upon binding by the ligands PD-L1 and PD-L2. PD-L1 (also known as B7-H1) is a transmembrane glycoprotein that may be expressed on tumor cells or tumor-infiltrating immune cells, while PD-L2 is primarily expressed on macrophages and DCs. The binding of PD-1 to PD-L1 causes downregulation of the T-cell response. PD-L1 expression reduces T-cell activation by binding to PD-1 and CD80, reducing CD28 costimulation. CTLA-4, another negative regulator of T-cell activation, is present on the cell surface of CD4+ and CD8+ T cells, where it binds to CD80 and CD86 (B7-1 and B7-2) to reduce CD28-mediated T-cell activation.

Knowing the normal distribution of PD-L1 and PD-L1/2 is important in understanding the adverse effects of the checkpoint inhibitors. PD-L1 is expressed not only on activated T cells, but also on double-negative (CD4-/CD8-) T cells in the thymus, activated NK T cells, B cells, monocytes, and immature Langerhans cells. PD-L1 is expressed on a diverse number of cell types, including antigen-presenting cells (APCs), vascular endothelial cells, pancreatic islet cells, and placenta, testes, and eye. PD-L2 is expressed on DCs and macrophages. PD-L1 is expressed in HNSCC in 50% to 60% of cases and is more common in those patients with HPV-associated HNSCC. The checkpoint inhibitors thus have a biological basis for use in HNSCC.

**Checkpoint Inhibitors in the Recurrent/Metastatic Setting**

Pembrolizumab is a humanized anti–PD-1 antibody. It was tested in patients with r/m HNSCC who were PD-L1+ in the KEYNOTE-012 trial. The initial cohort of the study included patients with any level of PD-L1 expression (>1% of tumor or immune cells) by immunohistochemistry (IHC). A 24-gene panel of interferon (IFN)-gamma–related genes, previously shown to be predictive of clinical outcome in the KEYNOTE-001 study, was also measured in tumor samples. Patients received pembrolizumab 10 mg/kg intravenously every 2 weeks. There were 104 patients screened, of whom 81 (78%) were PD-L1+. Of these, 60 patients were treated. Forty-nine of these 60 patients discontinued treatment, 35 because of progressive disease. Of the 60 that were treated, both p16+ (38%) and p16- (62%) patients were enrolled. Seventeen percent of patients experienced grade 3 to 4 drug-related adverse events (AEs), of which the most common were transaminase and hypotension. The most common low-grade AEs were fatigue, pruritus, nausea, decreased appetite, and rash. Overall response rate (ORR) by central review was 18%, with a numerically higher response rate of 25% in p16+ than in p16- patients (19%). The median OS was 13 months (95% CI, 5 to not reached) in the intention-to-treat population (n = 61) and 8 months (95% CI, 4 to not reached) for the p16 subgroup; it was not reached for the p16+ patients (95% CI, 8 to not reached) and the median duration of response among responders was 53 weeks. Higher levels of PD-L1 and IFN-gamma–related gene expression signature correlated with response. The pilot study also included 7 (12%) patients who had not previously received therapy for r/m disease. In the CheckMate 141 trial discussed below, the OS benefit with nivolumab was most prominent in those patients who had not received cetuximab previously, with hazard ratio (HR) = 0.55 (95% CI, 0.35-0.81) compared with HR = 0.81 (95% CI, 0.57-1.15) for those who had, suggesting that those who have not had treatment before are more likely to respond.

The pattern of care of first- or second-line treatment was not uniform; of the patients who were previously treated, 63% had received cetuximab and platinum therapy, while 25% had received platinum without cetuximab. Finally, HPV status was determined by the use of p16 IHC as a surrogate marker, and it has been shown that there are significant limitations of p16 as a surrogate marker in non-oropharyngeal sites. However, in this trial, only 2 patients had demonstrated nonoropharyngeal HPV+ primary tumors, both having tumors arising in the nasopharynx.

In the KEYNOTE-012 expansion cohort, 132 patients with r/m HNSCC, regardless of PD-L1 status, received a fixed dose of pembrolizumab 200 mg once every 3 weeks. ORR was again 18% (95% CI, 12%-26%); there was a statistically significant superior ORR for PD-L1+ versus PD-L1– patients (22% vs 4%; P = .021). Median duration of response was not reached in this cohort, and 6-month progression-free survival (PFS) and OS rates were 23% and 59%, respectively. Based on these data, pembrolizumab was approved by the FDA on August 5, 2016, for the treatment of patients with r/m HNSCC with disease progression on or after platinum-containing chemotherapy.

Nivolumab is a fully human immunoglobulin G4 (IgG4) anti–PD-1 monoclonal antibody. It was studied in a phase III trial (CheckMate 141) among patients with platinum-refractory HNSCC. The definition of platinum-refractory included patients with tumor progression or recurrence within 6 months after platinum-based chemotherapy, which could have been administered in the context of primary, adjuvant, or r/m disease. Patients were randomly assigned in a 2:1 ratio to intravenous nivolumab 3 mg/kg every 2 weeks or a standard investigator-chosen single-agent therapy of methotrexate, docetaxel, or cetuximab. The primary endpoint was OS and main secondary endpoints were PFS, ORR, and quality-of-life (QOL) assessments. Two hundred forty patients received nivolumab and 121 received standard therapy, with median OS of 7.5 months (95% CI, 5.5-9.1 months) in the nivolumab group versus 5.1 months (95% CI, 4.6 months) in the
standard-therapy group. There was no significant difference in PFS, with median PFS 2.0 months (95% CI, 1.9–2.1 months) versus 2.3 months (95% CI, 1.9–3.1 months) in the nivolumab and standard-therapy groups, respectively. However, PFS at 6 months was improved with nivolumab therapy at 19.7% versus 9.9% (P = .32). The response rate (RR) was 13.3% in the nivolumab-treated patients versus 5.8% in the standard-therapy group. The nivolumab group experienced fewer grade 3 or 4 drug-related AEs, with the most frequent AEs being fatigue, nausea, rash, decreased appetite, and pruritus. Additionally, patients treated with nivolumab experienced less decline in patient-reported QOL compared with those receiving standard therapy. Patients with PD-L1 expression of >1% (OS 8.7 vs 4.6 months for PD-L1 <1%) and p16+ tumors (OS 9.1 vs 4.4 months for p16– tumors) had a greater response to nivolumab than to standard therapy; OS was not significantly different between PD-L1– patients treated with nivolumab or standard of care (HR, 0.89; 5.7 vs 5.8 months). Nivolumab appeared beneficial no matter which standard-of-care agent was given, and was beneficial both in patients whose prior cisplatin exposure had been in the primary therapy setting as well as in those who had received cisplatin for r/m disease. Nivolumab was approved by the FDA on November 10, 2016, for the treatment of patients with r/m HNSCC with disease progression on or after a platinum-based therapy.34

Durvalumab is an IgG1 monoclonal antibody to PD-L1. It has shown activity in a phase II/III multicenter open-label study (NCT01693562) as monotherapy for multiple solid tumor types, including HNSCC.60,61 Fifty-one patients with HNSCC were evaluated for response; ORR was 12% (25% in PD-L1+ patients); and disease control at 24 weeks was 16% (25% in PD-L1+ patients). Ongoing trials are assessing durvalumab as monotherapy or in combination with the anti–CTLA-4 antibody tremelimumab in the first- and second-line recurrent or metastatic setting (Table 1).

Atezolizumab and avelumab are both humanized Mabs against PD-L1 that have been tested across all tumor types and show an acceptable safety profile.62 Avelumab is being used in combination with standard-of-care chemoradiation in locally advanced disease in a phase III trial (NCT02952586).

CTLA-4 Inhibitors

Ipilimumab is a fully humanized monoclonal antibody that targets CTLA-4. It is being used with cetuximab and intensity-modulated radiotherapy (RT) in the front-line setting to treat locally advanced HNSCC (NCT01935921). Tremelimumab (MedImmune) is a selective human IgG2 mAb that is also an inhibitor of CTLA-4.63

Biomarkers of Interest

It has been shown that PD-L1 expression correlates to increased RRs to anti–PD-L1 inhibitors.64,65 Challenges to the use of PD-L1 as a biomarker include fluctuation in expression at different time points, variation within tumor tissue,66,67 lack of uniformity in cutpoints employed in different trials, and multiple assays that introduce variability.

### Table 1. Checkpoint Inhibitor Trials in the Recurrent/Metastatic Setting for HNSCC.

<table>
<thead>
<tr>
<th>Agent</th>
<th>NCT ID Number</th>
<th>Phase</th>
<th>Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>NCT02252542</td>
<td>Phase III</td>
<td>Versus standard treatment</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02358031</td>
<td>Phase III</td>
<td>In combination with EXTREME regimen</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT0255097</td>
<td>Phase II</td>
<td>After progression on platinum and cetuximab</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02611940</td>
<td>Phase II</td>
<td>For nasopharyngeal SCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02538510</td>
<td>Phase I/II</td>
<td>With vemurafenib</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02718820</td>
<td>Phase I/II</td>
<td>With docetaxel</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02501096</td>
<td>Phase Ib/II</td>
<td>With lenvatinib</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02458179</td>
<td>Phase I/II</td>
<td>With avelumab, a second-generation Bruton TKI</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02941570</td>
<td>Phase III</td>
<td>With epacadostat</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02823574</td>
<td>Phase III</td>
<td>As monotherapy, compared with EXTREME regimen</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02823574</td>
<td>Phase II</td>
<td>As monotherapy and in combination with ipilimumab</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02488759</td>
<td>Phase I/II</td>
<td>With daratumumab, an anti-CD38 Mab</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02327078</td>
<td>Phase I/II</td>
<td>With epacadostat</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT0235918</td>
<td>Phase I/II</td>
<td>With varilumab, an anti-CD27 Mab</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02684253</td>
<td>Phase II</td>
<td>With RT</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT01693562</td>
<td>Phase I/II</td>
<td>Monotherapy</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT02551159</td>
<td>Phase III</td>
<td>Monotherapy or in combination with tremelimumab, compared with EXTREME</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT02369874</td>
<td>Phase III</td>
<td>Monotherapy or in combination with tremelimumab, based on PD-L1 expression</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT0270530</td>
<td>Phase II</td>
<td>Monotherapy, for PD-L1+ patients</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT0239044</td>
<td>Phase II</td>
<td>Monotherapy or in combination with tremelimumab, for PD-L1- patients</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT02525814</td>
<td>Phase II</td>
<td>With tremelimumab and chemotherapy</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT02490372</td>
<td>Phase II</td>
<td>With STAT 3 inhibitor (AZD9150) and CXCR2 antagonist (AZD5063)</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT03019003</td>
<td>Phase II</td>
<td>With tremelimumab and azacitidine</td>
</tr>
<tr>
<td>Avelumab</td>
<td>NCT02554812</td>
<td>Phase II</td>
<td>Combination with anti-CD137 or anti-OX-40</td>
</tr>
</tbody>
</table>

EXTREME indicates cetuximab/platinum/5-FU; HNSCC, head/neck squamous cell cancer; mAb, monoclonal antibody; NCT, national clinical trial; RT, radiation therapy; SCC, squamous cell carcinoma; TKI, tyrosine kinase.
are activating receptors involved in immunosurveillance expressed chemotherapies increase expression of NK cell group 2D ligands, which with IFN-beta immunotherapy, increases antitumor effect. Particularly, gemcitabine also selectively targets MDSC, and, in combination infiltration and antitumor responses both in vivo and in vitro. They are selectively killed by 5-fluorouracil (5-FU), causing CD8+ T-cell cancer by inhibiting CD8+ T cells or cytotoxic T lymphocytes (CTLs). c Regulatory T cells (Tregs) are selectively depleted by pembrolizumab monotherapy alone, while the CheckMate 021 trial compared pembrolizumab plus carboplatin/pemetrexed with chemotherapy alone. The KEYNOTE-021 study compared pembrolizumab plus various combinations of platinum-doublets with nivolumab monotherapy and with chemotherapy alone. Combination chemotherapy/ PD-1 agent arms in both trials had higher ORRs of 55% and 33% to 47% (across arms), respectively, as compared to historical rates with PD-1 treatment alone (44.8% and 19%, respectively). Analogously in HNSCC, pembrolizumab is being combined with platinum/5-FU/ cetuximab in the first-line r/m setting and with docetaxel in the second-line setting. Similarly, nivolumab is being combined with cisplatin/radiation in the frontline locally advanced setting. The use of combinatorial immunotherapy, or anti-PD-1/anti-PD-L1 and anti-CTLA-4 antibodies, may hold promise in HNSCC through a synergistic effect. They bind to their ligands at different points on Tcell development and have shown promise in preclinical models of HNSCC.

Rationale for Checkpoint Inhibitor Combinations

The activity of PD-1 inhibition in platinum-refractory HNSCC has led to interest in incorporating immune checkpoint inhibition into earlier lines of therapy, particularly in combination with conventional treatments. A significant body of evidence provides rationale for this strategy.

By increasing the presentation of tumor antigens, promoting immunogenic cell death, and influencing the tumor microenvironment, cytotoxic chemotherapy creates a favorable environment for synergy with checkpoint inhibitors. In mouse models, cyclophosphamide has been shown to deplete Tregs and limit their suppressive capability. Myeloid-derived suppressor cells (MDSCs) aid in immune tolerance to cancer by inhibiting CD8+ T cells or cytotoxic T lymphocytes (CTLs). They are selectively killed by 5-fluorouracil (5-FU), causing CD8+ T-cell infiltration and antitumor responses both in vivo and in vitro. Similarly, gemcitabine also selectively targets MDSC, and, in combination with IFN-beta immunotherapy, increases antitumor effect. Certain chemotherapies increase expression of NK cell group 2D ligands, which are activating receptors involved in immunosurveillance expressed on NK cells and CTLs, causing an increase in tumor-cell lysis. Anthracyclines and oxaliplatin cause immunogenic cell death via 2 mechanisms. The first is an increased engulfment of tumor cells by DCs, while the other is by triggering a release of high-mobility group box 1 protein from dying tumor cells that acts on toll-like receptor 4 (TLR-4) expressed by DCs, optimizing the presentation and processing of tumor antigens. Cisplatin has been shown to broaden the range of tumor antigens exposed to CTL responses in vivo. Additionally, in mouse models it sensitizes tumor cells to CTL-mediated attacks through upregulation of mannose-6-phosphate receptors. In breast cancer, neoadjuvant anthracycline-based chemotherapy has been shown to change the immune infiltrate of the tumor; those with an increase in tumor-infiltrating CTLs and a decrease in Tregs have significantly better rates of pathologic complete response (CR) at time of surgery. The method by which chemotherapy is administered can cause varying effects on the immune system. Dose-dense chemotherapy, a more frequent condensed administration of doses, has been shown to have improved disease-free survival (DFS) as adjuvant treatment for breast cancer and improved PFS for advanced ovarian cancer. In patients with ovarian cancer, dose-dense cisplatin + paclitaxel causes increase in CD8+ cytotoxic T cells, and this regimen decreases MDSCs as well as Tregs. Multiple chemotherapeutic agents have been shown to induce PD-L1 expression in tumor cells, and this upregulation has been associated with worse outcomes. This is another rationale for combination, with anti-PD-1/PD-L1 drugs, which have better response rates in this setting.

The combination of cytotoxic chemotherapy with checkpoint inhibitors can potentially provide more rapid disease control while waiting for immunotherapy response (the median time to response with pembrolizumab monotherapy was 8 weeks) and reduce tumor size to allow for better T-cell infiltration. Multiple trials in non–small-cell lung cancer (NSCLC) have tested anti-PD-1 antibodies with chemotherapy. The KEYNOTE-021 study compared pembrolizumab plus carboplatin/pemetrexed with chemotherapy alone, while the CheckMate 012 trial compared nivolumab plus various combinations of platinum-doublets with nivolumab monotherapy and with chemotherapy alone. Combination chemotherapy/PD-1 agent arms in both trials had higher ORRs of 55% and 33% to 47% (across arms), respectively, as compared to historical rates with PD-1 treatment alone (44.8% and 19%, respectively). Analogously in HNSCC, pembrolizumab is being combined with platinum/5-FU/cetuximab in the first-line r/m setting and with docetaxel in the second-line setting. Similarly, nivolumab is being combined with cisplatin/radiation in the frontline locally advanced setting.

The use of combination immunotherapy, or anti-PD-1/anti-PD-L1 and anti-CTLA-4 antibodies, may hold promise in HNSCC through a synergistic effect. They bind to their ligands at different points in Tcell development and have shown promise in preclinical models of HNSCC.

In vivo, antibodies targeting the 2 pathways differ in their immune effects, with CTLA-4 blockade causing increase in memory T cells and PD-1 blockade causing alteration of genes responsible for T-cell and NK function. Clinically, phase I and II trials in melanoma and NSCLC showed significantly improved response rates with nivolumab/ipilimumab as compared with monotherapy. In the r/m setting, anti-CTLA-4 drugs have been combined with nivolumab (anti-PD-1) in many trials in other solid tumors. Thus, there is rationale for the ongoing phase I/II trials of nivolumab/ipilimumab and durvalumab/tremelimumab.

The targeted therapies act on a variety of molecular pathways, generally have a more rapid onset of action with short-lived benefit, and can work synergistically with immunomodulatory agents. Cetuximab, a monoclonal antibody to EGFR, has been shown to colon cancer cell lines (in combination with chemotherapy) to promote activation of human DCs for antigen priming and to create a vigorous CTL response. Cetuximab acts via antibody-dependent cellular cytotoxicity through CD56+ NK cells in patients with metastatic colon cancer, but it has also been shown to act through complement-dependent cytotoxicity.

The targeted therapies act on a variety of molecular pathways, generally have a more rapid onset of action with short-lived benefit, and can work synergistically with immunomodulatory agents. Cetuximab, a monoclonal antibody to EGFR, has been shown to colon cancer cell lines (in combination with chemotherapy) to promote activation of human DCs for antigen priming and to create a vigorous CTL response. Cetuximab acts via antibody-dependent cellular cytotoxicity through CD56+ NK cells in patients with metastatic colon cancer, but it has also been shown to act through complement-dependent cytotoxicity.
in lung cancer cell lines.\textsuperscript{11,12} Cetuximab induces immunosuppressive Tregs that express CTLA-4,\textsuperscript{13} and it is being combined with ipilimumab in a phase I trial (NCT01935921).

The transcription factor signal transducer and activation of transcription 3 (STAT3) functions through an immunosuppressive pathway in which activation promotes expansion of MDSCs and Tregs, and causes abnormal DC differentiation.\textsuperscript{14,15} JAK2/STAT3 pathway-selective inhibitors have been shown in mouse models to promote differentiation of mature DCs, increase T-cell priming, and have an antitumor effect.\textsuperscript{15} Combinations of pembrolizumab with a JAK1 inhibitor and durvalumab with a STAT3 inhibitor are undergoing investigation in early-phase trials.

Activation of the PI3K/Akt pathway causes immune resistance by suppression of an antiapoptotic pathway (suppresses Mcl-1), and tumor cell lines that express Akt are resistant to T-cell killing.\textsuperscript{17} Inhibition of the Akt pathway with targeted therapy increases CTL killing of tumor cells in vitro.\textsuperscript{18} Pembrolizumab is being combined with a PI3K-delta inhibitor (INCB050465) while nivolumab is added to a PI3K-gamma inhibitor (IPI549) in phase I/II trials.

The histone deacetylase (HDAC) inhibitors deplete MDSCs, and in mouse models of metastatic cancer, they have been shown to be highly effective in combination with anti–PD-1/anti–CTLA-4 antibodies, completely curing metastatic disease.\textsuperscript{19} Another HDAC inhibitor, vorinostat, has been used in mouse models of melanoma, in which the mechanism of action is inhibition of the Fas/Fasl-dependent activation-induced death of T cells. In combination with anti–CTLA-4 antibody, there was a synergistic antitumor effect.\textsuperscript{20} Vorinostat with pembrolizumab is currently enrolling patients in phase I testing.

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that breaks down tryptophan, and when produced by activated DCs, it causes an inhibition of T-cell proliferation.\textsuperscript{21} Epacadostat, an oral selective inhibitor of IDO1, has had promising RBs in multiple solid tumor types (primarily advanced melanoma) in combination with pembrolizumab in a phase I study.\textsuperscript{22} There were 2 patients with HNSCC patients on the trial, both of whom had responses (1 partial, 1 stable disease). Epacadostat is being studied in the r/m HNSCC setting in combination with pembrolizumab and nivolumab.

5-azacitidine (Aza) is a DNA hypomethylating agent that is incorporated into DNA and blocks DNA methyltransferases. In NSCLC cell lines, it increases IFN signaling, which leads to upregulation of surface antigens and PD-L1.\textsuperscript{23,24} Another important pathway of Aza-related immune regulation is through cytosolic sensing of double-stranded RNA, releasing a type I IFN response that upregulates hypermethylated endogenous retrovirus genes.\textsuperscript{25} High expression of these “viral defense” genes correlates strongly with clinical benefit in ovarian cancer patients who have been treated with checkpoint inhibitor.\textsuperscript{26} In a mouse melanoma model, low-dose Aza enhanced the effect of anti–CTLA-4 therapy.\textsuperscript{27} Currently, Aza is being used in combination with durvalumab in early clinical trials.

RT also affects the immune system in ways that may be associated with immune exhaustion or activation. In a mouse model of colon cancer, RT increased new peptide formation, cell surface expression of major histocompatibility class (MHC) class I molecules, antigen presentation, and CTL recognition of irradiated cells.\textsuperscript{28} In another mouse model of melanoma, RT increased migration of antigen-presenting cells (APCs) to the tumor site, increased tumor-infiltrating lymphocytes (TILs) that secreted IFN-gamma, and increased circulating tumor antigens.\textsuperscript{29} The “abscopal effect” is a term that describes local RT causing tumor shrinkage at distant, nonirradiated sites, presumably through activation of the immune system.\textsuperscript{30,31} RT by itself has been shown to cause increased PD-L1 expression in mouse models.\textsuperscript{32} In a breast cancer mouse model, RT alone caused an increase in PD-L1 expression in tumor cells. When anti–PD-L1 antibody was given with RT, tumor growth was controlled, there was a decrease in MDSCs, and an abscopal effect was also demonstrated.\textsuperscript{33} In clinical case reports and small retrospective series, there has been evidence for the abscopal effect in NSCLC\textsuperscript{34} and melanoma.\textsuperscript{35} Specifically, in HNSCC, there are cell-line models that show chemotherapy with radiation enhances CTL killing and sensitization of HNSCC cells to the granule perforin/granzyme pathway of CTL killing, while downregulating bcl-2 (antiapoptotic gene) expression.\textsuperscript{36} In another metastatic breast cancer mouse model, local radiation with anti–CTLA-4 blockade showed increased improvement in metastatic burden.\textsuperscript{37} Based on this justification, phase I trials combining checkpoint inhibitors with RT in the upfront setting are ongoing. The optimal timing of the combination, management of immune AEs without incurring treatment interruptions, and the possibility of increased toxicity are all unanswered questions in this arena.

A phase II trial at Yale Cancer Center that may provide guidance on scheduling is currently enrolling patients with residual disease following chemoradiation to receive 3 months of pembrolizumab therapy prior to definitive resection (NCT02892201). Correlative studies will permit characterization of the postradiation tumor-immune microenvironment in relation to pembrolizumab response.

Surgery to remove primary tumor in metastatic breast cancer mouse models has been shown to reverse tumor-mediated immune suppression.\textsuperscript{15} This suggests that immune therapy in the adjuvant therapy setting may be more effective. The patients with HNSCC patients who should be targeted in the adjuvant setting are HPV–patients with locally advanced disease. Even with adjuvant cisplatin/RT, 3-year disease-free survival rates for this group are currently 30% to 50\%\textsuperscript{38,39}, with an absolute benefit of cisplatin/RT of 6.5\%.\textsuperscript{40,41} Ongoing trials of checkpoint inhibitors in the adjuvant setting with chemotherapy/RT are listed in Table 2.

Combinations of checkpoint inhibitors with vaccines, oncolytic tumor virus, and as monotherapy in the no-evidence-of-disease setting are also under investigation. The discovery of the means to augment the antitumor immune response in patients with HNSCC, and the recognition that a subset of patients treated with checkpoint inhibitors approach can expect long durations of disease control, are important breakthroughs in management of this difficult disease. Much remains to be learned, however, regarding patient selection, manipulation of the tumor microenvironment to enhance sensitivity to this approach, and the optimal means to integrate immunotherapy with definitive manage-
TABLE 2. Checkpoint Inhibitor Trials in the Frontline, Neoadjuvant, or Adjuvant Settings.

<table>
<thead>
<tr>
<th>Agent</th>
<th>NCT ID Number</th>
<th>Phase</th>
<th>Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab</td>
<td>NCT02252042, NCT02558260, NCT0819752</td>
<td>Phase I/II</td>
<td>With cis/RT for LA HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02707588</td>
<td>Phase II</td>
<td>With RT compared with cetuximab/RT for LA HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT0289209</td>
<td>Phase II</td>
<td>Post RT for patients with residual disease following CRT</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT0277385</td>
<td>Phase II</td>
<td>For nasopharyngeal SCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02266684</td>
<td>Phase I/II</td>
<td>With vorinostat in HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT0281748</td>
<td>Phase I/II</td>
<td>With docetaxel in HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02641093</td>
<td>Phase II</td>
<td>With lenvatinib in HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02609503</td>
<td>Phase II</td>
<td>With acaibrutinib, a second-generation Bruton TKI in HNSCC</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02769520</td>
<td>Phase II</td>
<td>With epacadostat in HNSCC</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02919643 NCT03021993</td>
<td>Phase II</td>
<td>As monotherapy, compared with EXTREME regimen in HNSCC and oral cavity SCC</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT03006367</td>
<td>Phase I/II</td>
<td>With daratumumab, an anti-CD38 in advanced or recurrent head and neck carcinoma</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02952586</td>
<td>Phase III</td>
<td>With epacadostat in HNSCC</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02999087</td>
<td>Phase III</td>
<td>With varilumab, an anti-CD27 mAb in HNSCC</td>
</tr>
</tbody>
</table>

Cis indicates cisplatin; CRT, chemoradiation therapy; EXTREME, cetuximab/platinum/5-FU; HNSCC, head/neck squamous cell cancer; LA, locally advanced; mAb, monoclonal antibody; NCT, national clinical trial; RT, radiation therapy; SCC, squamous cell cancer.

...and MHC class II agonist, has shown clinical activity in phase I trials for metastatic pancreatic, breast, and renal cell cancers. BMS-986016, an anti–LAG-3 antibody, is being used in phase I trials with nivolumab in HPV+ HNSCC (NCT02488759) as well as in advanced solid tumors including HPV+/- HNSCC (NCT01968109). AMG228 is another mAb in phase I trials for HNSCC. It targets glucocorticoid-induced tumor necrosis factor (TNF)-related receptor, which is expressed on the surface of CD25+CD4+ regulatory T cells and is costimulatory toward effector T cells. It is being used in a phase I clinical trial across multiple tumor types (NCT02437916).

TIM-3, a molecule selectively expressed on helper T cells, has been shown to be a negative regulator of T cells. Elevated expression of TIM-3 has been shown in patients with HNSCC to be correlated with worse clinical outcomes. Anti-TIM-3 antibodies (TSR-022) are in phase I clinical trials across tumor types as monotherapy (NCT02817633), with anti–PD-1 (NCT02608268) and with anti-TGF beta antibodies (NCT02947165).

Monalizumab (IPH2201) is a mAb-targeting NK cell lectin receptor (CD159) that is being tested in a phase I trial in combination with cetuximab in patients with r/m HNSCC; it is currently recruiting (NCT02643550).

Costimulatory Agonists

Toll-like receptors (TLRs)

Another immune therapy strategy is to enhance positive stimulatory pathways through cytokines and mAbs. The TLRs are a family of pathogen recognition receptors; the engagement of specific agonists induces activation of DCs and induces NK-cell–dependent lysis of tumor cells. TLR8 activates monocytes, NK cells, and DCs, and can potentially have a synergistic effect with chemotherapy or Mab treatment.

TIM-3, a molecule selectively expressed on helper T cells, has shown clinical activity in phase I trials for metastatic pancreatic, breast, and renal cell cancers. BMS-986016, an anti–LAG-3 antibody, is being used in phase I trials with nivolumab in HPV+ HNSCC (NCT02488759) as well as in advanced solid tumors including HPV+/- HNSCC (NCT01968109). AMG228 is another mAb in phase I trials for HNSCC. It targets glucocorticoid-induced tumor necrosis factor (TNF)-related receptor, which is expressed on the surface of CD25+CD4+ regulatory T cells and is costimulatory toward effector T cells. It is being used in a phase I clinical trial across multiple tumor types (NCT02437916).

TIM-3, a molecule selectively expressed on helper T cells, has been shown to be a negative regulator of T cells. Elevated expression of TIM-3 has been shown in patients with HNSCC to be correlated with worse clinical outcomes. Anti-TIM-3 antibodies (TSR-022) are in phase I clinical trials across tumor types as monotherapy (NCT02817633), with anti–PD-1 (NCT02608268) and with anti-TGF beta antibodies (NCT02947165).

Monalizumab (IPH2201) is a mAb-targeting NK cell lectin receptor (CD159) that is being tested in a phase I trial in combination with cetuximab in patients with r/m HNSCC; it is currently recruiting (NCT02643550).

Costimulatory Agonists

Toll-like receptors (TLRs)

Another immune therapy strategy is to enhance positive stimulatory pathways through cytokines and mAbs. The TLRs are a family of pathogen recognition receptors; the engagement of specific agonists induces activation of DCs and induces NK-cell–dependent lysis of tumor cells. TLR8 activates monocytes, NK cells, and DCs, and can potentially have a synergistic effect with chemotherapy or Mab treatment.

Additional, there is a phase I/II study of durvalumab/tremelimunab in combination with tumor microenvironment modulatory poly-ICLC, a TLR-3 agonist, in advanced, measurable, biopsy-accessible HNSCC (NCT02643303).

OX40

OX40 is a TNF receptor family member that can enhance T cell memory, proliferation, and antitumor activity. It has been found in abundance in the TILs of patients with advanced HNSCC. A phase I study is...
ongoing of MEDI6469, a mAb to OX40, in the neoadjuvant setting before surgical resection of locally advanced HNSCC (NCT02274155). In the r/m setting, it is being used as monotherapy or in combination with 4-1BB agonist PF-05082566, utomilumab (NCT02315066), and in combination with durvalumab or tremelimumab (NCT02205333).

**CD137 (4-1BB)**

Urelumab is a humanized mAb agonist of CD137, a TNF family receptor primarily expressed on activated T cells, DCs, and activated NK cells. An early phase I/II study reported in 2016 showed an ORR of 50% in patients with melanoma but only about 5% in the HNSCC cohort (n = 22) with the combination of urelumab and nivolumab. A phase Ib trial is ongoing, combining urelumab with cetuximab (NCT02110082) and with nivolumab (NCT02253992) in the r/m setting.

Another CD137 antibody is PF-05082566 (IgG2), or utomilumab. It is undergoing investigation in several phase I/II trials including with OX40 antibody (NCT02315066), with mogamulizumab (NCT02444793), with PD-1 inhibitor (NCT02179918; KEYNOTE 0036 [completed]), with PD-L1 inhibitor (NCT02554812), and as a single agent (NCT01307267).

**CD40L**

CD40L is expressed on activated CD4 T cells, and it binds to CD40 on APCs to activate them and to prime CD8 T cells. It is thought that this costimulatory pathway is downregulated in HNSCC immune escape. CP-870,893 is an anti-CD40 mAb that is being tested across multiple tumor types, including HNSCC, in a phase I trial as a monotherapy (NCT02225002). It has shown safety and efficacy across tumor types in phase I studies as monotherapy and in combination with chemotherapy.

**Viruses**

Several therapeutic vaccines have shown results in phase I/II trials of HNSCC. Peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (melanoma antigen E-A3 tumor-associated antigen, or MAGE-A3, a cancer-testis antigen) were developed as 2 separate vaccines using HLA-A1 and HLA-II T-cell epitopes of HPV16s and MAGE-A3 tumor-associated antigens. A phase I trial showed them to be well-tolerated and that they demonstrated antibody responses in the majority of patients (80% of the HPV16 cohort and 67% of the MAGE-A3 cohort). Cancer-testis antigens are good targets for peptide vaccines because they are specifically overexpressed on cancer cells as compared with normal tissue. Another phase II trial with 37 patients looked at a peptide vaccine derived from 3 such antigens and showed increased CD8 T-cell infiltration after vaccine use and that postvaccination peptide-specific CTL frequency was associated with OS; in addition, 1 patient demonstrated a CR.

A phase I trial tested adjuvant peptide-loaded DC-based vaccination against p53 in 16 patients; the data showed that it was well-tolerated, decreased Tregs levels post vaccination, and resulted in a 2-year DFS of 88%. A current phase I trial is examining modified vaccinia virus Ankara vaccine expressing p53 in combination with pembrolizumab (NCT02432963) in the r/m setting.

**PD-1/PD-L1**

Pembrolizumab, a humanized anti-PD-1 mAb, has given promising results in patients with vulvar intraepithelial neoplasia, but no results are yet in from HNSCC patients. ISA101 is being used in combination with nivolumab in a phase I trial (NCT02366306). INO-3112 is a DNA vaccine that combines 2 previously developed DNA vaccines (plasmids encoding HPV16 and HPV18 E6/E7) that results in an HPV-specific CD8+ T cell response. In a prospective phase I/IIa trial in adults with HPV+ HNSCC treated definitively with either chemoradiation or surgery, the vaccine was well-tolerated and HPV-specific T-cell immunity was generated by antibody titers.

The Hespecta vaccine family (the acronym is derived from HPV E Six Peptide Conjugated To Amplivant) includes ISA101 and ISA201, which are peptide vaccines derived from HPV16 E6 and E7 proteins. ISA101 has given promising results in patients with vulvar intraepithelial neoplasia, but no results are yet in from HNSCC patients. ISA101 is being used in monotherapy and in combination with nivolumab in a phase II trial (NCT02426892) for HPV16+ tumors. ISA201 is a second-generation vaccine in which 2 HPV16 E6 peptides are conjugated to a TLR2 agonist. A phase I trial (NCT02821494) of ISA201 is ongoing for HPV+ tumors that were definitively treated.

**Conclusions**

Novel immunotherapies have shown promising initial results in HNSCC. The checkpoint inhibitors pembrolizumab and nivolumab are now established in the treatment paradigm for metastatic disease. Moving forward, the results of many early-phase clinical trials should help guide the use of checkpoint inhibitors in the frontline, neoadjuvant, and adjuvant settings. In the future, combinations of immunotherapies and novel drugs may also replace monotherapy in r/m disease. We continue to wait eagerly for data from the phase I/II trials of vaccines and costimulatory agonists to see if they will become part of the treatment algorithm for HNSCC.

**Affiliations:** Tejas Suresh, MD, and Barbara A. Burtness, MD, are both physicians in the Department of Medical Oncology, Yale School of Medicine, New Haven, Connecticut.
THE EMERGING ROLE OF IMMUNOTHERAPY IN HEAD AND NECK SQUAMOUS CELL CANCER

Address correspondence to: Tejas Suresh, MD, Yale University School of Medicine, Department of Medical Oncology, 333 Cedar Street, WWW 221, PO Box 208028, New Haven, CT 06520-8028. E-mail: tejas.suresh@yale.edu.

Financial disclosures: None

References

For the remaining references, please visit www.gotoper.com/publications/ajho/2017/2017june/.